Semaglutide outcome trials
This entry has large human trials. Their populations and outcomes give the results a much more useful shape than a general claim about peptides.
The kidney study
The FLOW trial enrolled 3,533 people with type 2 diabetes and chronic kidney disease. It counted kidney failure, a fall of at least 50% in estimated kidney filtration, and death from kidney or cardiovascular causes. That combined outcome occurred less often with semaglutide than with placebo.
For me, a kidney-failure outcome carries unusual weight. Kidney failure is a consequential event, and the population has a defined disease burden. Both facts make the finding useful to understand. They also mark its reach: this was a diabetes-and-kidney-disease trial, so its result describes that group.
Semaglutide copies GLP-1, a gut hormone released after a meal. Chemical changes protect it from rapid breakdown and help it bind albumin, a plentiful blood protein. The resulting medicine lasts much longer than the natural hormone. It promotes insulin release when blood sugar is high, suppresses inappropriate glucagon release and slows stomach emptying.
Heart events in different groups
The SELECT trial studied 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. Cardiovascular death, nonfatal heart attack and nonfatal stroke were counted together. Semaglutide reduced that combined outcome compared with placebo.
An earlier trial, SUSTAIN-6, studied people with type 2 diabetes and high cardiovascular risk. Its combined cardiovascular outcome was also lower with semaglutide. Diabetic-retinopathy complications, however, occurred more often. The safety discussion connects that eye finding with existing retinopathy and rapid improvement in blood sugar.
The two trials occupy different places in this collection. I hesitate at a sentence that simply says “heart protection” and leaves the people out. SELECT's participants already had cardiovascular disease. SUSTAIN-6's participants had diabetes and elevated cardiovascular risk. Those details make the result more concrete.
Weight and appetite
In STEP 1, adults with overweight or obesity without diabetes had mean weight changes of -14.9% with semaglutide and -2.4% with placebo at 68 weeks. Those are group averages under trial conditions.
The rodent appetite experiments reached a different level of detail: mice and rats ate less, changed food preferences and lost weight without a fall in energy expenditure. The investigators mapped effects across several brain regions. That anatomical work was done in rodents; it offers a mechanism to investigate alongside human outcomes.
Semaglutide also appears in the direct obesity comparison with tirzepatide. At 72 weeks, mean weight change was -13.7% with semaglutide and -20.2% with tirzepatide in 751 adults with obesity without type 2 diabetes. The tirzepatide entry places that result beside the earlier diabetes comparison. I prefer the comparisons with their original settings attached.
Tolerability and label warnings
The semaglutide safety review found mainly transient, mild-to-moderate gastrointestinal effects and increased biliary disease, including gallstones. Nausea affected roughly one-third of patients in the reviewed diabetes data. Rare pancreatic and thyroid-cancer signals remained unresolved because events were uncommon.
The label's thyroid C-cell tumour warning comes from rodent findings. A personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication, even though a causal thyroid-cancer increase in humans has not been established. Pancreatitis remains a label warning; severe, persistent abdominal pain warrants medical assessment. Gallbladder disease and the retinopathy finding require their own attention.
Weight loss includes lean tissue as well as fat. Substantial regain after stopping, and diffuse hair shedding associated with rapid weight change, complicate the picture further. Semaglutide is contraindicated in pregnancy. Its oral formulation has absorption requirements, and medicines with a narrow safe blood-level range may need closer monitoring during treatment changes. Those are matters for the prescriber and pharmacist reviewing the actual medicines.
Anecdotal accounts add quieter food thoughts, reduced cravings and sometimes less interest in alcohol, alongside burping, bowel changes, fatigue and altered taste. These accounts are not clinical evidence of cause or frequency. I give the unpleasant details space because a large average weight change leaves much of the day-to-day burden undescribed.
Approved uses and preparations
FDA-approved uses include type 2 diabetes, chronic weight management, reduction of major cardiovascular events in certain adults, and a liver-disease indication added in 2025. Injectable and oral formulations have different approved uses and instructions. These are prescription medicines.
During a US shortage, compounded semaglutide became more widely available. The FDA received reports of dosing errors, hospital care and questionable active ingredients; the compounding pathway narrowed after the shortage ended in 2025. Compounded preparations are not FDA-approved. The evidence for the studied medicine cannot certify the contents of another preparation.
Semaglutide is not specifically prohibited by the World Anti-Doping Agency in the records discussed here, although athletes need the current list. Canada and categories explains why US approval history cannot supply a Canadian regulatory answer.